Lung cancer patients' comorbidities and attendance of German ambulatory physicians in a 5-year cross-sectional study.
Journal
NPJ primary care respiratory medicine
ISSN: 2055-1010
Titre abrégé: NPJ Prim Care Respir Med
Pays: England
ID NLM: 101631999
Informations de publication
Date de publication:
28 01 2021
28 01 2021
Historique:
received:
08
07
2020
accepted:
07
12
2020
entrez:
29
1
2021
pubmed:
30
1
2021
medline:
29
10
2021
Statut:
epublish
Résumé
The majority of lung cancer patients are diagnosed with an advanced stage IV, which has short survival time. Many lung cancer patients have comorbidities, which influence treatment and patients' quality of life. The aim of the study is to describe comorbidities in incident lung cancer patients and explore their attendance of ambulatory care physicians in Germany. In the observed period, 13,111 persons were first diagnosed with lung cancer (1-year incidence of 36.4 per 100,000). The mean number of comorbidities over 4 quarters was 30.77 ± 13.18; mean Charlson Comorbidity Index was 6.66 ± 2.24. In Germany, ambulatory care physicians most attended were general practitioners (2.6 quarters with contact within 4 quarters). Lung cancer was diagnosed by a general practitioner in 38% of the 13,111 incident patients. The average number of ambulatory care physician contacts over 4 quarters was 35.82 ± 27.31. High numbers of comorbidities and contacts in ambulatory care are common in patients with lung cancer. Therefore, a cross-sectoral and interdisciplinary approach is required for effective, patient-centred care. This was a 5-year cross-sectoral study, based on the InGef research database, which covers anonymized health insurance data of 7.2 million individuals in Germany. Incident lung cancer patients in a 5-year period (2013-2017) were identified. Descriptive statistics were calculated for sociodemographic characteristics, comorbidities, and attendance of ambulatory care physicians.
Identifiants
pubmed: 33510177
doi: 10.1038/s41533-020-00214-8
pii: 10.1038/s41533-020-00214-8
pmc: PMC7844218
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2Références
Lung Cancer. 2015 Feb;87(2):186-92
pubmed: 25498829
Pneumonol Alergol Pol. 2016;84(3):186-92
pubmed: 27238182
Radiologe. 2020 May;60(5):430-439
pubmed: 32060562
Pharmacoepidemiol Drug Saf. 2016 Jan;25(1):106-9
pubmed: 26530279
CA Cancer J Clin. 2016 Jul;66(4):337-50
pubmed: 26891458
Eur J Cancer Care (Engl). 2017 Mar;26(2):
pubmed: 26840784
Z Evid Fortbild Qual Gesundhwes. 2020 Nov;156-157:75-81
pubmed: 32859557
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2009 May;52(5):557-70
pubmed: 19343279
J Cancer Res Clin Oncol. 2017 May;143(5):895-904
pubmed: 28188361
Trials. 2018 Oct 24;19(1):583
pubmed: 30355358
J Med Internet Res. 2020 Jan 29;22(1):e15102
pubmed: 32012060
Eur J Cancer. 2010 Aug;46(12):2225-34
pubmed: 20471248
Oral Oncol. 2019 Sep;96:1-6
pubmed: 31422200
Palliat Med. 2018 Apr;32(4):838-850
pubmed: 29343169
Transl Behav Med. 2018 May 23;8(3):503-508
pubmed: 29800404
PLoS One. 2019 Aug 8;14(8):e0220848
pubmed: 31393931
J Geriatr Oncol. 2016 Mar;7(2):64-7
pubmed: 26948726
Cancer Epidemiol Biomarkers Prev. 2015 Jul;24(7):1079-85
pubmed: 26065838
BMC Cancer. 2020 Mar 24;20(1):250
pubmed: 32209058
Fam Pract. 2018 Jul 23;35(4):481-487
pubmed: 29385434
Lung Cancer. 2015 Dec;90(3):528-33
pubmed: 26480866
Eur J Cancer Care (Engl). 2018 Jan;27(1):
pubmed: 28983996
Gesundheitswesen. 2018 Jan;80(1):27-33
pubmed: 27171729
Eur J Cancer Care (Engl). 2017 Nov;26(6):
pubmed: 28295783
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Urol Oncol. 2017 Apr;35(4):150.e17-150.e23
pubmed: 28041997
Postgrad Med J. 2014 Jun;90(1064):305-10
pubmed: 24676985